<DOC>
	<DOCNO>NCT00722735</DOCNO>
	<brief_summary>To compare bacteriological eradication rate Finafloxacin Ciprofloxacin female patient uUTI .</brief_summary>
	<brief_title>Finafloxacin 300 mg Twice Day ( b.i.d . ) Versus Ciprofloxacin 250 mg Twice Day ( b.i.d ) Patients With Lower Uncomplicated UTI ( uUTI )</brief_title>
	<detailed_description>Patients clinical sign symptom uUTI high probability require number bacteria urine , measure positive test nitrite /or leucocyte esterase mean dipstick enrol study . Only patient bacterial count equal 10e5 cfu/mL include efficacy analysis . At Baseline , patient randomly assign ( 2:1 ) receive Finafloxacin 300 mg Ciprofloxacin 250 mg , follow double-dummy design , ie Group 1 receive Finafloxacin tablets + Ciprofloxacin placebo capsule Group II receive Ciprofloxacin capsule + Finafloxacin placebo tablet . The treatment last total 3 day . The microbiological result compare baseline microbiology . If concentration initial pathogen urine equal 10e3 cfu/mL post-therapy culture compare baseline , define bacteriological eradication . Microbiological assessment perform well . Evaluation bacteria reinfection relapse perform , base microbiology result . The status clinical improvement cure consider additionally .</detailed_description>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>1 . Female patient 18 55 year uUTI . 2 . Two follow sign symptom uUTI : dysuria , frequency , urgency , miction pain , suprapubic pain , gross hematuria , turbid urine malodorous urine . 3 . Able supply midstream , clean catch urine sample microbiological analysis . 4 . The result dipstick indicate high probability require number bacteria . 5 . Be able communicate study personnel . 6 . Has give write consent participate study . 1 . Female patient sign symptom upper urinary tract infection ( e.g . fever , flank pain ) indicating complicate UTI . 2 . Male patient 3 . History evidence functional anatomical abnormality urinary tract ( e.g . acute pyelonephritis ) , diabetes mellitus immunosuppression . 4 . Recurrent cystitis 3 episode past 12 month . 5 . Clinical symptom 7 day Baseline . 6 . Psychiatric , neurological behavior disorder . 7 . Clinically significant serious unstable physical illness . 8 . Known uncontrolled condition hypertension symptomatic hypotension , know ischemic heart disease history myocardial infarction ( within 12 month prior study enrolment ) , coronary artery bypass surgery percutaneous transluminal coronary angioplasty . 9 . Existence surgical medical condition might interfere distribution , metabolism excretion drug , i.e . impaired renal hepatic function , diabetes mellitus , chronic symptom pronounce constipation diarrhea condition associate total partial obstruction urinary tract . 10 . Antibiotic intake 2 week study enrolment . 11 . Failed UTI therapy within 2 month study inclusion . 12 . Expectancy concomitant administration antibiotic , sucralfate divalent trivalent cation iron antacid contain magnesium , aluminium calcium intake course study . 13 . Clinically abnormal vital sign , ECG finding safety laboratory result Baseline . 14 . Known hypersensitivity contraindication use fluoroquinolones . 15 . History tendon lesion rupture quinolone treatment . 16 . Any malignant disease history malignant neoplasm carcinoma situ cervix basal cell carcinoma skin , within last 5 year Baseline . 17 . Current diagnosis history substance abuse . 18 . Exposure investigational drug 30 day prior Baseline . 19 . Pregnant nursing woman , woman childbearing potential use effective contraceptive method study , e.g . oral ( stable dos least 3 month prior Baseline ) injectable ( stable dos least 2 month prior Baseline ) contraceptives , intrauterine device ( least 2 month prior Baseline ) , doublebarrier method , contraceptive patch , female sterilization condom . 20 . The patient , plan enrol employee involve study investigator involve institution include study sponsor . 21 . Inability lack motivation participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>uncomplicated Urinary Tract Infection Women</keyword>
	<keyword>Antibacterial Chemotherapy</keyword>
	<keyword>Proof-of-Concept</keyword>
</DOC>